ADIPOQ and metabolic dysfunction-associated steatotic liver disease: In a comparative analysis, adiponectin outperformed several metabolic markers in differentiating NAFLD subtypes, with an AUC of 0.643–0.644 (95% CI: 0.089–0.345, P < 0.001) (85).